Poseida Therapeutics to Feature Non-Clinical Data of P-KLKB1-101 for Treating Hereditary Angioedema at ACAAI 2024
Shots:
- Poseida will highlight non-clinical data of P-KLKB1-101, a liver-directed genetic medicine using the Cas-CLOVER gene editing system, for treating HAE at ACAAI 2024 under title, ‘Highly Specific Non-Viral Gene Editing with P-KLKB1-101 for Hereditary Angioedema’
- P-KLKB1-101 achieved efficient KLKB1 editing & reduced kallikrein with off-target effects below 0.1% in primary human hepatocytes and produced dose-dependent reductions in kallikrein levels, with effects lasting over 180 days in humanized mouse model. A single dose of 0.125 mg/kg resulted in a 58% reduced kallikrein levels
- Interim non-human primate data showed favorable tolerability and liver editing. Lead optimization increased potency by 29%
Ref: Poseida Therapeutics | Image: Poseida Therapeutics
Related News:- Poseida Therapeutics’ P-BCMA-ALLO1 Gains the US FDA’s Regenerative Medicine Advanced Therapy Designation for R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
